Incretin therapy for obesity: efficacy, safety, and compliance
Clinical review for general practice · 26.05.2026 · 7 (2) · 115-122
DOI: 10.47407/kr2026.7.2.00779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 26.05.2026. Verfasst von Mekan R Orazov und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Obesity remains one of the major comorbidities in the today’s world’s population that is of pandemic nature. Unfortunately, the rapid annual increase in the prevalence of obesity as a multisystemic disorder affecting almost all organs and systems is acknowledged. It has been proven that obesity increases the risk of polysomatic, carcinogenic disorders, including gynecological ones, and contributes to epigenetic remodeling of progeny genomes, inducing the endocrine/metabolic and cardiovascular disorders in the long term. The review provides details of the issue of efficacy, safety, and compliance in terms of incretin therapy for obesity. Keywords: obesity, preclinical obesity, clinical obesity, diagnostic criteria, glucagon-like peptide-1 receptor agonist, dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist, semaglutide, tirzepatide.
Zitieren
APA
Orazov, M. R., Radzinskiy, V. E., Mikhaleva, L. M., Balan, V. E., & Dolgov, E. D. (2026). Incretin therapy for obesity: efficacy, safety, and compliance. Clinical review for general practice, 7(2), 115-122. https://doi.org/10.47407/kr2026.7.2.00779
Vancouver
Orazov MR, Radzinskiy VE, Mikhaleva LM, Balan VE, Dolgov ED. Incretin therapy for obesity: efficacy, safety, and compliance. Clinical review for general practice. 2026;7(2):115-122. doi:10.47407/kr2026.7.2.00779
BibTeX
@article{Orazov2026,
author = {Orazov, Mekan R and Radzinskiy, Viktor E and Mikhaleva, Liudmila M and Balan, Vera E and Dolgov, Evgeniy D},
title = {Incretin therapy for obesity: efficacy, safety, and compliance},
journal = {Clinical review for general practice},
year = {2026},
volume = {7},
number = {2},
pages = {115--122},
doi = {10.47407/kr2026.7.2.00779}
}
EUVIMED